Intraocular Lenses Lawsuit

Bausch + Lomb intraocular lenses have been recalled due to reports of toxic anterior segment syndrome (TASS), a severe inflammatory eye reaction that can cause lasting damage. Those affected may be able to seek compensation from an intraocular lens lawsuit.

At Sokolove Law, we have over 45 years of experience holding companies accountable for putting patients at risk. Call (800) 995-1212 now for a free case review.

Get a Free Case Review

About the EnVista Lawsuit & Bausch + Lomb Recall

Intraocular lenses (IOLs) are clear, artificial lenses implanted during cataract surgery or refractive lens exchange. These devices replace the eye’s natural lens and are intended to help correct vision issues.

However, certain Bausch + Lomb enVitsa® IOLs have been linked to an increased risk of toxic anterior segment syndrome (TASS) due to defects in the raw materials used to manufacture the lenses, leading to an enVista IOL recall.

Lawsuits against Bausch + Lomb claim the company failed to ensure the safety of their intraocular lenses before releasing them to the public, putting thousands of patients at risk.

If you or a loved one was diagnosed with TASS after receiving a Bausch + Lomb IOL, you may be able to seek compensation from an intraocular lens lawsuit.

At Sokolove Law, we’ve secured more than $1.6 Billion for clients harmed by dangerous medical devices or drugs. Let us fight for you.

Get the Help You Deserve

We’ve helped thousands of families hold powerful health care companies accountable. Find out if you may be able to file an intraocular lens lawsuit.

Get a Free Case Review

Bausch and Lomb Intraocular Lens Recall 2025

On April 3, 2025, Bausch and Lomb initiated a voluntary recall of their enVista line of intraocular lenses due to reports of toxic anterior segment syndrome.

The 2025 enVista lens recall includes:

  • EnVista Aspire IOL (all models starting with EA)
  • EnVista Aspire Toric IOL (all models starting with ETA)
  • EnVista Envy IOL (all models starting with EN)
  • EnVista Envy Toric IOL (all models starting with ETN)
  • EnVista Monofocal Toric IOL (all models starting with ETE)
  • EnVista Monofocal IOL (all models starting with EE)

The U.S. Food & Drug Administration (FDA) shared the company’s initial enVista lens recall notice in April and designated it as a Class I recall in May following an investigation into the affected lenses.

A Class I recall is the agency’s most serious recall designation, reserved for medical devices that may cause severe injury or death.

Patients who begin experiencing discomfort after IOL surgery are encouraged to contact their eye doctor immediately.

Toxic Anterior Segment Syndrome Symptoms​ & Complications

Toxic anterior segment syndrome is a sudden inflammation inside the front part of the eye. This rare condition typically develops 12-48 hours after cataract surgery, though delayed-onset cases have also been reported.

TASS occurs when a toxic substance enters the eye during or after surgery, causing irritation and inflammation. Patients may experience eye pain, swelling, blurred vision, and sensitivity to light in the days after their surgery.

In some cases, toxic anterior segment syndrome may lead to:

  • Additional surgeries
  • Cornea damage
  • Glaucoma
  • IOL removal
  • Pain
  • Vision loss

EnVista IOL lawsuits claim that defects in the materials used to manufacture Bausch + Lomb’s IOLs may have triggered these severe inflammatory reactions in the eye.

“When clusters of TASS cases appear across multiple practices, attention must shift toward exogenous agents introduced during surgery — whether they be medications, IOLs, or OVDs.”
– Glaucoma Today

While most cases of TASS can be treated with aggressive steroid treatment, some patients may be left with permanent eye damage.

Who Can File an EnVista Lawsuit for Eye Damage?

Patients trust that the medical devices they receive are safe. When a defective device causes injury, those affected may have the right to hold the manufacturer accountable in court.

You may be able to file an enVista lawsuit if you or a loved one:

  • Received an intraocular lens implant manufactured by Bausch + Lomb
  • Was diagnosed with toxic anterior segment syndrome (TASS) after surgery

There’s only a limited amount of time to file an IOL lawsuit due to state laws called statutes of limitations, so it’s important to act fast. Once the deadline in your case passes, you won’t be able to seek justice again.

Call (800) 995-1212 now to find out if you may qualify for an intraocular lens lawsuit settlement. It costs nothing to speak with us.

How to File an EnVista Lens TASS Lawsuit

At Sokolove Law, we’re committed to making the legal process as easy and stress-free as possible. If you have a case, our team can handle all of the legal legwork on your behalf, so you can focus on your health.

Filing an enVista lens lawsuit generally involves your attorney:

  • Providing a free case review to determine your eligibility to file a claim
  • Gathering evidence linking your TASS diagnosis to a Bausch + Lomb IOL, like medical records and product information
  • Submitting the paperwork for your intraocular lenses lawsuit before any legal deadlines
  • Negotiating an IOL settlement with the defendant(s)
  • Presenting your case at trial if a settlement isn’t reached

By filing an enVista lens TASS lawsuit against Bausch + Lomb, you may be able to secure compensation for medical bills, lost wages, pain and suffering, and more.

Get Help from Our Intraocular Lens Lawsuit Lawyers

When patients undergo cataract surgery, they expect improved eyesight — not severe complications that could lead to permanent vision loss.

At Sokolove Law, our intraocular lens lawyers:

  • Have the resources to take on major corporations like Bausch + Lomb
  • Can help families in all 50 states seek justice
  • Don’t charge any upfront costs or hourly fees

With more than 45 years of experience and over $1.6 Billion total secured for patients harmed by dangerous medical devices and drugs, we have what it takes to fight for you.

Call (800) 995-1212 now or fill out our contact form to get started with a free case review. Our team is standing by to answer any questions you may have.

Bausch and Lomb Product Recall FAQs

What is the Bausch and Lomb lens recall in 2025?

In April 2025, Bausch + Lomb recalled their enVista intraocular lenses due to an increased risk of toxic anterior segment syndrome (TASS), a serious inflammatory reaction that can cause permanent eye damage.

The FDA classified this as a Class I recall, a designation that is reserved for products that may cause serious injuries or death.

Contact Sokolove Law now if you were diagnosed with TASS after receiving an intraocular lens implant. You may be eligible for compensation from a Bausch + Lomb lawsuit settlement.

Who can file an IOL lawsuit?

Anyone who received an enVista intraocular lens implant and was later diagnosed with toxic anterior segment syndrome (TASS) may be eligible to file an IOL lawsuit against Bausch + Lomb, the product’s manufacturer.

How much does an intraocular lens lawyer charge?

At Sokolove Law, there are no upfront costs or hourly fees to work with our intraocular lens lawyers.

We operate on a contingency-fee basis, which means you pay nothing unless we secure compensation on your behalf.

Is there a Bausch and Lomb class action lawsuit​?

Currently, enVista intraocular lens lawsuits are being filed individually, rather than as part of a Bausch + Lomb class action lawsuit.

Filing your case individually may help ensure that any potential enVista settlement or verdict you receive reflects the true cost of your pain and medical bills.

Call (800) 995-1212 now to see if you may be able to file a Bausch + Lomb lawsuit. It costs nothing to speak with us.

  1. American Academy of Ophthalmology. “Toxic Anterior Segment Syndrome.” Retrieved from: https://eyewiki.org/Toxic_Anterior_Segment_Syndrome.
  2. Cleveland Clinic. “IOLs (Intraocular Lenses).” Retrieved from: https://my.clevelandclinic.org/health/articles/25099-iols-intraocular-lenses.
  3. Glaucoma Today. “Spotlight on TASS.” Retrieved from: https://glaucomatoday.com/articles/2025-mar-apr/spotlight-on-tass.
  4. Ophthalmology Times. “Bausch + Lomb identifies issue in enVista platform, returns product to market.” Retrieved from: https://www.ophthalmologytimes.com/view/bausch-lomb-identifies-issue-in-envista-platform-returns-product-to-market.
  5. U.S. Food & Drug Administration. “Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses in the U.S.” Retrieved from: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bausch-lomb-announces-voluntary-recall-envista-aspiretm-envista-envytm-and-certain-envistar.
  6. U.S. Food & Drug Administration. “Class 1 Device Recall.” Retrieved from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=213219.